Débora Barton

732 total citations
26 papers, 299 citations indexed

About

Débora Barton is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Débora Barton has authored 26 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Immunology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Débora Barton's work include CAR-T cell therapy research (18 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune cells in cancer (7 papers). Débora Barton is often cited by papers focused on CAR-T cell therapy research (18 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune cells in cancer (7 papers). Débora Barton collaborates with scholars based in United States, United Kingdom and Italy. Débora Barton's co-authors include Stefan Glück, Denise A. Yardley, Nadia Harbeck, Pierfranco Conté, Adam Brufsky, Javier Cortés, Joyce O’Shaughnessy, Michael Klichinsky, Daniel Cushing and Andreas Schneeweiß and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Débora Barton

25 papers receiving 292 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Débora Barton United States	7	228	99	83	70	66	26	299
Francesca Sarno Spain	6	232 1.0×	41 0.4×	112 1.3×	108 1.5×	75 1.1×	9	333
Ahmed Raji Iraq	3	204 0.9×	68 0.7×	42 0.5×	132 1.9×	97 1.5×	8	319
Songwei Feng China	11	84 0.4×	75 0.8×	69 0.8×	61 0.9×	130 2.0×	21	266
Gabriella Albert United States	4	128 0.6×	55 0.6×	47 0.6×	131 1.9×	94 1.4×	5	307
Amber Beyer United States	4	153 0.7×	59 0.6×	46 0.6×	158 2.3×	97 1.5×	4	345
Joseph E. Grossman United States	8	193 0.8×	58 0.6×	49 0.6×	77 1.1×	62 0.9×	30	290
Jinzhi Lai China	7	118 0.5×	37 0.4×	70 0.8×	43 0.6×	104 1.6×	17	223
Okan Gultekin Sweden	6	155 0.7×	29 0.3×	44 0.5×	82 1.2×	82 1.2×	10	263
Corey Gallen United States	4	137 0.6×	53 0.5×	45 0.5×	143 2.0×	87 1.3×	6	281
Stephanie O. Dudzinski United States	5	126 0.6×	46 0.5×	48 0.6×	132 1.9×	68 1.0×	12	268

Countries citing papers authored by Débora Barton

Since Specialization

Citations

This map shows the geographic impact of Débora Barton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Débora Barton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Débora Barton more than expected).

Fields of papers citing papers by Débora Barton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Débora Barton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Débora Barton. The network helps show where Débora Barton may publish in the future.

Co-authorship network of co-authors of Débora Barton

This figure shows the co-authorship network connecting the top 25 collaborators of Débora Barton. A scholar is included among the top collaborators of Débora Barton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Débora Barton. Débora Barton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malki, Monzr M. Al, Alla Keyzner, Hyung C. Suh, et al.. (2024). A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.. Journal of Clinical Oncology. 42(16_suppl). TPS2678–TPS2678. 1 indexed citations

Thomas, Sajeve, Brian S. Henick, Rom S. Leidner, et al.. (2024). Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2542–2542.

Malki, Monzr M. Al, Alla Keyzner, Hyung C. Suh, et al.. (2024). TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial. Transplantation and Cellular Therapy. 30(2). S1–S2. 4 indexed citations

Abdou, Yara, E. Claire Dees, Joanne Mortimer, et al.. (2023). Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors. Cancer Research. 83(8_Supplement). CT241–CT241. 2 indexed citations

Reiss, Kim A., Joanne Mortimer, Paula R. Pohlmann, et al.. (2023). 635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. SHILAP Revista de lepidopterología. A726–A726. 1 indexed citations

Malki, Monzr M. Al, Alla Keyzner, Hyung C. Suh, et al.. (2023). Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation. Blood. 142(Supplement 1). 2090–2090. 4 indexed citations

Reiss, Kim A., Naoto T. Ueno, Yuan Yuan, et al.. (2022). 633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors. Regular and Young Investigator Award Abstracts. A664–A664. 5 indexed citations

Yuan, Yuan, Naoto T. Ueno, Melissa L. Johnson, et al.. (2022). A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2533–2533. 37 indexed citations

Yuan, Yuan, et al.. (2022). A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.. Journal of Clinical Oncology. 40(4_suppl). TPS668–TPS668. 4 indexed citations

10.

Reiss, Kim A., Yuan Yuan, Naoto T. Ueno, et al.. (2022). 634 A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors. Regular and Young Investigator Award Abstracts. A665–A665. 6 indexed citations

11.

Reshef, Ran, Hyung C. Suh, Monzr M. Al Malki, et al.. (2022). Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation. Blood. 140(Supplement 1). 7468–7469. 1 indexed citations

12.

Yuan, Yuan, Naoto T. Ueno, Melissa L. Johnson, et al.. (2022). A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2677–TPS2677. 2 indexed citations

13.

Bauml, Joshua, et al.. (2021). Abstract CT204: A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Cancer Research. 81(13_Supplement). CT204–CT204. 1 indexed citations

14.

Bauml, Joshua, Natalie S. Grover, Daniel Cushing, et al.. (2021). A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS2660–TPS2660. 3 indexed citations

15.

Reiss, Kim A., Yuan Yuan, Débora Barton, et al.. (2021). 951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data. SHILAP Revista de lepidopterología. A1000–A1000. 9 indexed citations

16.

Sarnaik, Amod, Sajeve Thomas, Diwakar Davar, et al.. (2019). Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.. Journal of Clinical Oncology. 37(8_suppl). 136–136. 3 indexed citations

17.

Yardley, Denise A., Rob Coleman, Pierfranco Conté, et al.. (2018). nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology. 29(8). 1763–1770. 91 indexed citations

18.

Vogelzang, Nicholas J., Karim Fizazi, John M. Burke, et al.. (2016). Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European Urology. 71(2). 168–171. 45 indexed citations

19.

Karavasilis, Vasilios, et al.. (2008). Prognostic value of the rate of rise of CA 125 after first line chemotherapy for survival in patients with relapsed ovarian cancer. Journal of Clinical Oncology. 26(15_suppl). 5544–5544. 3 indexed citations

20.

Martorella, Peter H., et al.. (1991). Training Teachers in Interactive Video Instructional Applications. Computers in the Schools. 8(1-3). 293–302. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact